Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

911 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PHF19 inhibition as a therapeutic target in multiple myeloma.
Schinke CD, Bird JT, Qu P, Yaccoby S, Lyzogubov VV, Shelton R, Ling W, Boyle EM, Deshpande S, Byrum SD, Washam C, Mackintosh S, Stephens O, Thanendrarajan S, Zangari M, Shaughnessy J Jr, Zhan F, Barlogie B, van Rhee F, Walker BA. Schinke CD, et al. Among authors: qu p. Curr Res Transl Med. 2021 Jul;69(3):103290. doi: 10.1016/j.retram.2021.103290. Epub 2021 Apr 22. Curr Res Transl Med. 2021. PMID: 33894670 Free PMC article.
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.
Shaughnessy JD Jr, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, Tian E, Hanamura I, van Rhee F, Anaissie E, Epstein J, Nair B, Stephens O, Williams R, Waheed S, Alsayed Y, Crowley J, Barlogie B. Shaughnessy JD Jr, et al. Among authors: qu p. Blood. 2011 Sep 29;118(13):3512-24. doi: 10.1182/blood-2010-12-328252. Epub 2011 May 31. Blood. 2011. PMID: 21628408 Free PMC article.
Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).
Khan R, Dhodapkar M, Rosenthal A, Heuck C, Papanikolaou X, Qu P, van Rhee F, Zangari M, Jethava Y, Epstein J, Yaccoby S, Hoering A, Crowley J, Petty N, Bailey C, Morgan G, Barlogie B. Khan R, et al. Among authors: qu p. Haematologica. 2015 Sep;100(9):1214-21. doi: 10.3324/haematol.2015.124651. Epub 2015 May 28. Haematologica. 2015. PMID: 26022710 Free PMC article. Clinical Trial.
The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma.
Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, Zangari M, Rasche L, Weinhold N, Alapat D, Bellamy W, Ashby C, Mattox S, Epstein J, Yaccoby S, Barlogie B, Hoering A, Bauer M, Walker BA, Davies FE, Morgan GJ. Thanendrarajan S, et al. Among authors: qu p. Haematologica. 2017 Sep;102(9):e364-e367. doi: 10.3324/haematol.2017.168872. Epub 2017 May 26. Haematologica. 2017. PMID: 28550191 Free PMC article. No abstract available.
Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes.
Mehdi SJ, Johnson SK, Epstein J, Zangari M, Qu P, Hoering A, van Rhee F, Schinke C, Thanendrarajan S, Barlogie B, Davies FE, Morgan GJ, Yaccoby S. Mehdi SJ, et al. Among authors: qu p. Br J Haematol. 2019 Feb;184(4):578-593. doi: 10.1111/bjh.15669. Epub 2018 Nov 8. Br J Haematol. 2019. PMID: 30408155 Free PMC article. Clinical Trial.
911 results